Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).
Conferences
Lee, K-W; Moehler, MH; Cunningham, D; Wainberg, ZA; Uronis, HE; Oh, D-Y; Kim, I-H; Shim, BY; Sym, SJ; Altura, RA; Stilian, MC; Parker, EC ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
February 1, 2023
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
February 1, 2023
Volume
41
Start / End Page
TPS484 / TPS484
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Lee, K.-W., Moehler, M. H., Cunningham, D., Wainberg, Z. A., Uronis, H. E., Oh, D.-Y., … Klempner, S. J. (2023). Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41, pp. TPS484–TPS484).
Lee, Keun-Wook, Markus H. Moehler, David Cunningham, Zev A. Wainberg, Hope Elizabeth Uronis, Do-Youn Oh, In-Ho Kim, et al. “Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).” In JOURNAL OF CLINICAL ONCOLOGY, 41:TPS484–TPS484, 2023.
Lee K-W, Moehler MH, Cunningham D, Wainberg ZA, Uronis HE, Oh D-Y, et al. Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish). In: JOURNAL OF CLINICAL ONCOLOGY. 2023. p. TPS484–TPS484.
Lee, Keun-Wook, et al. “Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023, pp. TPS484–TPS484.
Lee K-W, Moehler MH, Cunningham D, Wainberg ZA, Uronis HE, Oh D-Y, Kim I-H, Shim BY, Sym SJ, Altura RA, Stilian MC, Parker EC, Klempner SJ. Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish). JOURNAL OF CLINICAL ONCOLOGY. 2023. p. TPS484–TPS484.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
February 1, 2023
Volume
41
Start / End Page
TPS484 / TPS484
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis